What should be monitored in a patient on methimazole for hyperthyroidism?

In patients receiving methimazole for hyperthyroidism, it is essential to monitor a complete blood count (CBC) and liver enzymes due to the potential side effects associated with the medication. Methimazole can lead to agranulocytosis, a severe drop in white blood cell count, which increases the risk of infections. Regular monitoring of the complete blood count helps detect any significant changes in white blood cell levels early, ensuring timely management if complications arise.

Additionally, liver enzyme tests are important because methimazole can cause hepatic injury in some patients. Monitoring liver function through these enzyme tests allows for the identification of any hepatotoxic effects, ensuring that the medication can be adjusted or discontinued if necessary to prevent serious liver damage.

Thus, the combination of monitoring both the complete blood count and liver enzymes provides a comprehensive approach to patient safety while on methimazole, allowing for early detection of adverse effects that could complicate treatment.